Nitric Oxide is a highly reactive gas, and nitrogen oxides have long been recognized as toxic environmental pollutants and the Inhaled Nitric Oxide use in the neonatal period is associated with an increased risk of neonatal cancers, and specifically liver tumours as a new potential risk factor.
& it is a pulmonary vasodilator that is used to treat conditions associated with reversible vasoconstriction & pulmonary hypertension. It plays a major role in regulating vascular muscle tone & has emerged as a treatment for hypoxemic respiratory failure in newly born infants associated with persistent high pulmonary vascular pressure.
Recent research indicated that inhaled Nitric Oxide can be applied in various diseases & studies suggested that inhaled Nitric Oxide is a safe and effective agent to determine the vasodilatory capacity of the pulmonary vascular bed. Clinical Applications of Inhaled NO include Pulmonary Hypertension of the newborn, Preventing Chronic Lung Disease in the Newborn, Safety and Cost-Effectiveness of Inhaled NO in the Newborn. Inhaled NO is the first vasodilator to produce truly selective pulmonary vasodilation & large number of laboratory and clinical research studies have been performed to delineate the biochemistry, physiology. side effects, and clinical efficacy of inhaled NO in various diseases of children and adults. The clinical use of inhaled NO has become widespread.The birth database that the authors used included just over 1 million births between 2000 and 2011, with the outcome of interest being malignant disease diagnosed at any time, so the average follow up was about 6.5 years. There were just over 1000 cancers diagnosed, so about 0.1% of live born babies. 2.2% of the total birth cohort of babies were in the NICU database, whereas nearly 6% of the cancers were among NICU patients.
To know more, PS: https://goo.gl/x6YWyX